Poster Presentations
37th Congress of European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
Wednesday, October 13, 2021 – Friday, October 15, 2021
Presentation
B&T Cell-Mediated Autoimmune Disease Drug Development Summit
Wednesday, October 6, 2021
Poster Presentation
50th Annual European Society for Dermatological Research (ESDR) Meeting
Wednesday, September 22, 2021 – Saturday, September 25, 2021
Presentation
Virtual R&D Day: Update on the Preclinical and Clinical Development of IMU-935
Monday, July 12, 2021
Play Audio Recording
Poster Presentation
The International Federation of Psoriasis Association’s 6th World Psoriasis & Psoriatic Arthritis Conference 2021
Wednesday, June 30, 2021 – Saturday, July 3, 2021
Presentation
IMU-838 in Multiple Sclerosis: Phase 3 Program in RRMS & Phase 2 Trial in PMS
Thursday, July 1, 2021
Play Audio Recording
Poster Presentation
2021 Virtual AAN Annual Meeting
Saturday, April 17, 2021 – Thursday, April 22, 2021
Play Audio Recording
Poster Presentation
30th Annual Meeting of the Society for Virology
Wednesday, March 24, 2021 – Friday, March 26, 2021
Presentation
Main Phase 2 Analysis IMU-838 in Moderate COVID-19 & Phase 2 Proof-of-Concept Study IMU-838 in PSC
February 18, 2021
Play Audio Recording
Article
Clinical relevance of intestinal barrier dysfunction in common gastrointestinal diseases
Andreas Muehler, Jason R Slizgi, Hella Kohlhof, Manfred Groeppel, Evelyn Peelen and Daniel Vitt
World Journal of Gastrointestinal Pathophysiology; 2020 December 12; 11(6):114-130
Published: December 12, 2020
doi: 10.4291/wjgp.v11.i6.114
Article
IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro
Friedrich Hahn, Christina Wangen, Sigrun Häge, Antonia Sophia Peter, Gerhard Dobler, Brett Hurst, Justin Julander, Jonas Fuchs, Zsolt Ruzsics, Klaus Überla, Hans-Martin Jäck, Roger Ptak, Andreas Muehler, Manfred Gröppel, Daniel Vitt, Evelyn Peelen, Hella Kohlhof and Manfred Marschall
Viruses 2020, 12, 1394
Published: December 5, 2020
doi: 10.3390/v12121394
Poster Presentation
MSVirtual2020 / 8th Joint ACTRIMS-ECTRIMS Meeting
Friday, September 11, 2020 – Sunday, September 13, 2020
Presentation
IMU-838 Phase 2 Data EMPhASIS Trial in RRMS
Friday, September 11, 2020
Play Audio Recording
Presentation
IMU-838 Phase 2 Top-Line Data EMPhASIS Trial in RRMS
Monday, August 3, 2020
Article
Novel Dihydroorotate Dehydrogenase Inhibitors with Potent Interferon-Independent Antiviral Activity against Mammarenaviruses In Vitro
Yu-Jin Kim, Beatrice Cubitt, Yingyun Cai, Jens H. Kuhn, Daniel Vitt, Hella Kohlhof, Juan C. de la Torre
Viruses 2020, 12, 821
Published: July 29, 2020
doi: 10.3390/v12080821
Presentation
Immunic’s Inaugural Virtual R&D Day
Tuesday, May 19, 2020
Play Audio Recording
Article
Vidofludimus calcium, a next generation DHODH inhibitor for the treatment of relapsing-remitting multiple sclerosis
Andreas Muehler, Evelyn Peelen, Hella Kohlhof, Manfred Gröppel, Daniel Vitt
Multiple Sclerosis and Related Disorders, Volume 43, 2020
Published online: May 6, 2020
ISSN 2211-0348 / doi: 10.1016/j.msard.2020.102129
Article
Safety, Tolerability and Pharmacokinetics of Vidofludimus calcium (IMU-838) After Single and Multiple Ascending Oral Doses in Healthy Male Subjects
Andreas Muehler, Hella Kohlhof, Manfred Groeppel & Daniel Vitt
European Journal of Drug Metabolism and Pharmacokinetics
Published online: May 2, 2020
ISSN 0378-7966 / doi: 10.1007/s13318-020-00623-7
Abstract
Design, Rationale and Baseline Characteristics of the Randomized Double-blind Phase II Clinical Trial of Vidofludimus calcium (IMU-838) in Relapsing-Remitting Multiple Sclerosis (4558)
Robert Fox, Heinz Wiendl, Nicola De Stefano, Johann Sellner, Andreas Mühler
Neurology Apr 2020, 94 (15 Supplement) 4558
Published online: April 14, 2020
Presentation
IBD Innovate Conference: Product Development for Crohn’s and Colitis
Wednesday, December 4, 2019
New York
Poster Presentation
United European Gastroenterology Week (UEGW)
Tuesday, October 22, 2019
Barcelona, Spain
Article
The Selective Oral Immunomodulator Vidofludimus in Patients with Active Rheumatoid Arthritis: Safety Results from the COMPONENT Study
Andreas Muehler, Hella Kohlhof, Manfred Groeppel & Daniel Vitt
Drugs in R&D
Published online: October 16, 2019
ISSN 1174-5886 / doi: 10.1007/s40268-019-00286-z
Poster Presentation
Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2019
Wednesday, September 11, 2019
Stockholm, Sweden
Presentation
GI Inflammatory Diseases Summit (GIIDS)
Monday, June 24, 2019
Boston
Poster Presentation
2nd Conference on Molecular Mechanisms of Inflammation
Tuesday, June 4, 2019
Trondheim, Norway